19 Oct 2017

Stephenson Harwood advises Novacyt SA on AIM IPO

Linkedin

Law firm Stephenson Harwood LLP has advised Novacyt SA on its €25 million AIM IPO.

Novacyt is incorporated in France, but headquartered in Cambridge and is an international specialist in clinical diagnostics, with a particular focus on cancer and infectious diseases. The company, currently listed on Euronext Growth Paris, will also list on AIM and has raised a total of €9.7m (before expenses). Commencement of trading on AIM is scheduled for 1 November 2017.  The funds will help Novacyt expand its international profile and manufacturing capacity.

Novacyt's listing on AIM will make it the first company with a dual-listing on Euronext Growth Paris and AIM.

The Stephenson Harwood team was led by head of corporate Andrew Edge, who was supported by IP partner Alexandra Pygall, senior associate Tom Page (corporate), associates Victoria Silver, Charlotte Lewis and Kate Hewitson (all corporate), Lucy Calvert (IP) and Chloe Scott (employment) and trainees Amir Mahdavi and Karen Cheng (corporate).  Employee incentives advice was delivered by head of incentives, Barbara Allen, and senior associate Anika Chandra.

Linkedin

KEY CONTACT

Andrew Edge

Andrew Edge
Partner

T:  +44 20 7809 2102 M:  +44 7771 921 780 Email Andrew | Vcard Office:  London

MEDIA CONTACT

Rose Russell
Communications & PR Executive

T: +44 20 7809 2961 
Email Rose